| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.32 | 4e-07 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.18 | 3e-06 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.22 | 1e-05 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.26 | 4e-05 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.22 | 9e-05 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.15 | 0.0001 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0002 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.23 | 0.0002 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0003 |